首页> 外文OA文献 >270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy

【2h】

270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy

机译：270大型单现场机构检测对体细胞和种系的一致性经验，BRCA1 / 2卵巢癌患者的致病性突变有资格获得PARP抑制剂治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
I Akaev; C Chau; N Dabab; S Rahimi; F Gardner; CC Yeoh;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients (vol 152, pg 270, 2019) [J] . Gynecologic Oncology: An International Journal . 2020,第1期

机译：化疗和PARP抑制剂在重预处理的BRCA1 / 2突变卵巢癌（BMOC）患者（Vol 152，PG 270,2019）
2. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2 [J] . Amit M. Oza, Anna V. Tinker, Ana Oaknin, Gynecologic Oncology: An International Journal . 2017,第2期

机译：PARP抑制剂Rucaparib在高级卵巢癌和种系或体细胞BRCA1或BRCA2突变中的抗肿瘤抑制剂Rucaparib：来自研究10和ARIEL2的数据的综合分析
3. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study [J] . Coleman Robert L., Sill Michael W., Bell-McGuinn Katherine, Gynecologic Oncology: An International Journal . 2015,第3期

机译：NRG肿瘤/妇科肿瘤小组研究对有效，高度选择性的PARP抑制剂veliparib进行II期评估，以治疗携带种系BRCA1或BRCA2突变的患者持续或复发的上皮性卵巢癌，输卵管或原发性腹膜癌
4. Identification of potential long non-coding RNA biomarkers for breast cancer patients with somatic BRCA1 mutations from RNA-Seq datasets [C] . Jia-Hua Cai, Yu-Ching Chen, Hsueh-Ting Chu, IEEE International Conference on Bioinformatics and Bioengineering . 2018

机译：鉴定来自RNA-SEQ数据集的乳腺癌患者乳腺癌患者的潜在长期非编码RNA生物标志物
5. Dolo?anje Mutacij v Genih BRCA1/2 Iz citolo?kega Materiala Pri Raku jaj?nikov, Jajcevodov in Primarnem Peritonealnem Seroznem Karcinomu =BRCA1/2 mutation testing from cytological samples in patients with ovarian, tubal and primary peritoneal serous cancer [D] . Gornjec, Andreja. 2020

机译：从自我癌症中确定基因Krca1 / 2中的突变吗？
6. A phase II evaluation of the potent highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian fallopian tube or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – an NRG Oncology/Gynecologic Oncology Group study [O] . Robert L. Coleman, Michael W. Sill, Katherine Bell-McGuinn, -1

机译：NRG肿瘤/妇科肿瘤小组研究对强效高度选择性的PARP抑制剂veliparib在患有生殖系BRCA1或BRCA2突变的患者中持续或复发的上皮性卵巢癌输卵管或原发性腹膜癌的II期评估
7. Corrigendum to ‘Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients’ Gynecologic Oncology 152 (2019) 270-277 [O] . V. Rodriguez-Freixinos, L. Fariñas-Madrid, M. Gil-Martin, 2020

机译：严重预处理BRCA1 / 2突变卵巢癌（BMOC）患者妇科肿瘤152（2019）270-277勘察勘察和PARP抑制剂

270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy

著录项

引文网络

相似文献

相关主题

期刊订阅